Bal Pharma Announces 39th AGM on Sep 24, 2026; Declares ₹1.20 Dividend
Bal Pharma Limited will hold its 39th AGM on September 24, 2026, via VC/OAVM. The company proposed a dividend of ₹1.20 per equity share for FY 2025-26. Key dates for e-voting and book closure are set for September 2026. The AGM will also address financial statements, director re-appointment, cost auditor remuneration, and related party transactions.
The AGM announcement, dividend declaration, and proposed changes in directorships are significant corporate events that can impact investor perception and corporate governance. The renewal of a related party transaction contract up to ₹30 crore also warrants a medium impact.
The announcement is a routine corporate event (AGM notice) and includes standard proposals like dividend declaration and director re-appointment. While the dividend is a positive aspect, the overall tone is informational and procedural, making NEUTRAL the most appropriate sentiment.
Bal Pharma Limited has announced its 39th Annual General Meeting (AGM) for the Financial Year 2025-26, scheduled to be held on Thursday, September 24, 2026, at 11:30 AM IST. The meeting will be conducted through Video Conferencing (VC) and Other Audio-Visual Means (OAVM). The company also proposed to declare a dividend of ₹1.20 per equity share of ₹10 each (12% on face value) for the financial year ended March 31, 2026.
Key dates for the AGM include the Record Date for Final Dividend and E-voting on September 17, 2026, and the Book Closure Period from September 18, 2026, to September 24, 2026. E-voting will commence on September 21, 2026, at 9:00 AM IST and conclude on September 23, 2026, at 5:00 PM IST.
During the AGM, shareholders will consider and adopt the Audited Standalone and Consolidated Financial Statements for FY 2025-26. Additionally, Mr. Ravindra Kumar Kothari is proposed for re-appointment as a Director. Special business includes ratifying the remuneration for Cost Auditors for FY 2026-27, renewing a contract with Desa Marketing International with an aggregate value not exceeding ₹30 Crore in a financial year, and approving changes in the designations of Mr. Ravindra Kumar Kothari from Non-Executive Director to Whole-Time Director and Mr. Virupakshaya Himesh from Whole-Time Director to Non-Executive Director, with effect from October 1, 2026.
What to do with a filing like this
Bal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bal Pharma Limited. Read the original for the full detail.